unknown
Stage
1
Investors
About
Braveheart Bio is a clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions. The company is advancing BHB-1893, a selective cardiac myosin inhibitor, through late-stage clinical development with the goal of establishing a new standard of care for patients with HCM.
Explore Braveheart Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.